Publication: Transvaginal color Doppler sonographic evaluation of the uterus in postmenopausal women on daily raloxifene therapy
2
Issued Date
2002-01-01
Resource Type
ISSN
13697137
Other identifier(s)
2-s2.0-0036001258
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Climacteric. Vol.5, No.2 (2002), 156-159
Suggested Citation
A. Chittacharoen, U. Theppisai, J. Manonai Transvaginal color Doppler sonographic evaluation of the uterus in postmenopausal women on daily raloxifene therapy. Climacteric. Vol.5, No.2 (2002), 156-159. doi:10.1080/cmt.5.2.156.159 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/20559
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Transvaginal color Doppler sonographic evaluation of the uterus in postmenopausal women on daily raloxifene therapy
Author(s)
Other Contributor(s)
Abstract
Objective: To evaluate the effect of raloxifene on the endometrium and the uterus by transvaginal color Doppler sonography. Methods: The study group was composed of 34 asymptomatic postmenopausal women. All had been treated with raloxifene 60 mg/day for 6 months. The patients underwent transvaginal color Doppler sonography before starting raloxifene and after treatment. The uterus was scanned by transvaginal ultrasound to evaluate the pulsatility (PI) and resistance (RI) indices of both uterine arteries. The mean values for the uterine arteries were analyzed. Results: The mean age of the women was 57.56 ± 4.44 years (range 48-64 years), and mean number of years since the menopause was 8.67 ± 5.44 (range 1-25 years). The mean endometrial thickness (3.62 ± 1.13 vs. 3.59 ± 0.95 mm) and uterine volume (40.67 ± 18.36 vs. 38.05 ± 19.47 ml) were not significantly different before starting treatment and after treatment (p > 0.05). The mean values of the PI (3.49 ± 1.56 vs. 3.90 ± 1.38) and RI (0.94 ± 0.11 vs. 0.98 ± 0.10) of the uterine arteries were not significantly different before starting treatment and after treatment (p > 0.05). Conclusion: Daily therapy with raloxifene did not stimulate the endometrium, the uterus or uterine blood flow.